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Background
With an estimated worldwide prevalence of 2.2%,
hepatitis C virus (HCV) is one of the most preva-
lent chronic viral infections in the world.1
Incarcerated populations have dramatically high-
er rates of HCV infection than non-incarcerated
populations. Approximately 2.0% of the United
States (US) non-incarcerated population has
been infected with HCV; 1.3% are chronically
infected. In contrast, seroprevalence studies
have found HCV infection rates ranging between
16-43%2,3,4 among incarcerated populations; 12-
35% of inmates have chronic infection.  
HCV is a viral infection transmitted primarily
through blood and blood products.
Approximately 75% of acutely infected patients
will develop chronic infection, and 20% of those
with chronic infection develop cirrhosis within 20
years.6 While there is no vaccine for HCV, effec-
tive strategies for preventing transmission exist.5
Additionally, the current standard-of-care treat-
ment regimen, pegylated interferon (PEG IFN)
alfa plus ribavirin (RBV), has demonstrated high-
er sustained virologic response (SVR) rates,
defined as the absence of HCV RNA in serum by
a sensitive test at the end of treatment and six
months later, compared to standard interferon.
PEG IFN alfa plus RBV is safe and efficacious in
both HCV mono-infected7 and HIV/HCV co-
infected patients. 
Because nearly one-third of all HCV-infected per-
sons pass through correctional facilities each
year8, and will eventually return to the communi-
ties from whence they came, providing HCV
screening, testing, treatment and prevention edu-
cation (including education regarding re-infection
and basic primary prevention for those who do
not test HCV-infected) within corrections could
have important public health implications. Testing
and, when appropriate, treating HCV-infected
inmates could reduce disease transmission in the
communities to which inmates return.   
Testing
Currently, the United States Task Force for
Preventive Services recommendations caution
against routinely screening patients for HCV
infection,9 as screening tests have low positive
predictive values (PPV) if the prevalence of the
disease in the population being screened is less
than 10%.  Those recommendations do not apply
to drug-using populations. The most efficient
means of HCV transmission is through injection
drug use; estimates of HCV prevalence for injec-
tion drug users (IDUs) are as high as 90% in
some regions.10 Since a large number of inmates
have previously or currently inject drugs and
because approximately one-third of HCV-infected
persons pass through corrections every year,
most experts recommend that prison inmates be
screened for HCV infection.11
Accordingly, Centers for Disease Control and
Prevention (CDC) recommendations regarding
HCV screening in correctional settings includes
the following statements: (1) All inmates should
be questioned regarding risk factors for HCV
infection during entry medical examinations, and
those with risk factors should be tested for HCV;
(2) The sensitivity of risk factor-based screening
should periodically be determined by seropreva-
lence surveys, in combination with ascertainment
of demographic and risk factor information.
Serologic testing of expanded groups of inmates
or all inmates is recommended when: (2a) self-
reported history of risk factors alone identifies
<75% of anti-HCV positive inmates or (2b) the
prevalence of risk factors for HCV infection,
including injection drug use, is known to be high
(>75%), and a high prevalence (>20%) of HCV
infection exists among inmates who deny risk fac-
tors.5
Persons who received a blood or organ trans-
plant prior to 1992 should also be tested.4
Although transmission from exposure to an
infected sexual partner is less efficient, any indi-
vidual who has had multiple sexual partners or
who believes one of his or her partners is HCV-
infected, should be tested. Lastly, persons with
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unexplained elevations of aminotransferase levels, those who have
ever been on hemodialysis, and those with HIV infection, should all
be tested for HCV infection.2
Laboratory Diagnosis of HCV
Eighty percent of individuals with acute HCV infection are asympto-
matic.12 Identification of HCV infection is accomplished by initially
testing for antibodies to HCV (anti-HCV.) To prevent false-positive
results, testing should include an antibody screening assay, followed
by confirmatory testing of positive results with a more specific assay
(Table 1.)  Because a positive test result for anti-HCV does not dis-
tinguish between acute and chronic infection, HCV RNA testing
should be performed in individuals who test positive for anti-HCV.
Chronic infection is defined as the presence of HCV RNA for a mini-
mum of six months.13
HCV Genotypes
There are six different HCV genotypes.  Because HCV genotype is
the strongest predictor of response to treatment,14 genotype should
be determined in all HCV-infected persons prior to treatment. Studies
indicate that individuals infected with HCV genotype 1 are the least
likely to achieve a SVR, while those infected with genotypes 2 and 3
are much more likely to achieve a SVR.1 It should be noted that 95%
of HCV-infected African Americans are infected with genotype 1,
while only 65% of non-African Americans are infected with genotype
1.15 Two tests, which are not FDA-approved, are currently available
for HCV genotyping. These include the Trugene HCV 5'NC
Genotyping Kit (Visible Genetics) and the Inno LiPA HCV II
(Innogenetics.)  These tests fail to identify HCV genotype in less than
3% of HCV-infected persons, and may display a mixed genotype in
1%-4% of HCV-infected persons.2
Liver Biopsy
Various protocols exist in a number of correctional systems to deter-
mine who should receive a liver biopsy and tehse are not consistent
among different state department of corrections.  This point is impor-
tant if liver biopsy is considered a prerequisite for treatment, because
those who do not qualify for biopsy would not be considered candi-
dates for treatment. The following criteria have all been used to deter-
mine who should receive a liver biopsy: (1) two elevated ALT levels
greater than two times the upper limit of normal, at least three months
apart; (2) one ALT level greater than two times the upper limit of nor-
mal; (3) one ALT level greater than 1.5 times the upper limit of nor-
mal; (4) any ALT elevation at any time (but not persistently normal
ALT); (5) all HCV-infected persons.  The California DOC offers liver
biopsy to all HCV-infected persons 45 or older, regardless of ALT lev-
els, while those younger than 45 must have elevated ALT levels. It
should be noted that the available literature does not clearly lend sup-
port to any particular criteria as listed, and that decisions in individual
cases should be guided by the totality of the clinical picture for each
patient.  
Liver biopsy results reveal information regarding the extent of fibrosis
(staging) and degree of hepatic inflammation (grading), thus helping
the patient and provider decide on the course, and urgency, of thera-
py.16 Various scoring systems for defining staging and grading have
been developed. The components of two of these scoring systems
are shown in Table 2.
More-than-portal fibrosis on liver biopsy (Metavir score of >2 or an
Ishak score of >3) is an important predictor of future progression of
liver disease and the need for HCV treatment.11 Scoring is usually
provided in the pathology laboratory report.
Non-invasive tests, including the FibroSURE test and aspartate
aminotransferase to platelet radio index (APRI), may be alternatives
to liver biopsy. Both tests are limited in that they poorly differentiate
between stages 1 and 2 fibrosis. Often this represents the cutoff
wherein many protocols determine whether patients will or will not
receive interferon/RBV therapy. Therefore, non-invasive tests are
only helpful when severe liver damage or cirrhosis is the expected
finding.
Because of decreased SVR rates in HCV genotype 1-infected
patients, many clinicians obtain a liver biopsy for these patients to
guide treatment recommendations.  HCV genotype 2- and 3-infected
patients have a higher likelihood of achieving a SVR and so some
advocate treating all such patients, regardless of liver disease sever-
ity, and without liver biopsy.  Current AASLD recommendations state
that a liver biopsy should be performed, regardless of ALT levels, and
for all genotypes, when the results will influence whether treatment is
recommended.  A biopsy is not required to initiate therapy. 7
Treatment
The current standard-of-care treatment regimen for HCV mono-infec-
tion and HIV/HCV co-infection is PEG IFN alfa plus RBV.10 The two
FDA-approved PEG IFN products; PEG IFN alfa-2a (Pegasys®,
Hoffman-La Roche) and PEG IFN alfa-2b (Peg-Intron®, Schering-
Plough Corporation) have demonstrated similar indicators of both
treatment response and adverse events, but further studies are need-
ed to compare the efficacy of the two products.6,10
If, t 12 weeks of treatment, the early virologic response (EVR) indi-
cates that there has not been a 2 log decline in HCV RNA relative to
baseline HCV RNA, the patient is unlikely to achieve a SVR and treat-
ment should be discontinued.17
Treatment is not recommended for individuals under certain circum-
stances (Table 3.)
All HCV-infected patients should receive hepatitis A virus (HAV) and
HBV vaccinations if they are non-immune (see this months IDCR-o-
gram.)
Drug Side Effects
Side effects of PEG IFN alfa may include neutropenia, thrombocy-
topenia, depression, hypothyroidism, irritability, concentration and/or
memory disturbances, fatigue, headaches, nausea, vomiting, weight
loss, insomnia, and flu-like symptoms.18
Side effects of RBV may include hemolytic anemia, fatigue, and rash.
Pregnant women should not be prescribed RBV, as it can result in
birth defects. During treatment and for six months post-treatment,
m n and women should use contraception methods to avoid preg-
nancy.11 RBV is contraindicated in patients on dialysis and in patients
who have severely elevated creatinine clearance.
2
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Table 1: FDA-Approved HCV Laboratory Tests
Antibody Screening Tests
w Abbott HCV EIA 2.0 (Abbott Laboratories)
w ORTHO HCV Version 3.0 ELISA (Ortho-Clinical 
Diagnostics)
w VITROS Anti-HCV assay (Ortho-Clinical Diagnostics)
Confirmatory Tests
w Chiron RIBA HCV 3.0 SIA (Chiron Corp)
w AMPLICOR HCV Test, Version 2.0 
(Roche Molecular Systems)
w COBRAS AMPLICOR HCV test 
(Roche Molecular Systems)
Stage
0
1
2
3
4
5
6
Metavir System
No fibrosis
Periportal fibrosis
expansion
Portal-portal (P-P)
septae 
Portal-central (P-C)
septae
Cirrhosis
-
-
Ishak System
No fibrosis
Fibrous expansion of some
portal areas, with or without
short fibrous septae
Fibrous expansion of most
portal areas, with or without
short fibrous septae
Fibrous expansion of most
portal areas with occasional
P-P bridging
Fibrous expansion of portal
areas with marked bridging
(P-P or P-C)
Marked bridging (P-P or P-
C) with occasional nodules
Cirrhosis
Table adapted from: AASLD practice guideline: diagnosis, management,
and treatment of hepatitis C.
Table 2: HCV Scoring Systems
3All adverse effects tend to decrease in severity after the initial few
weeks of treatment, and may be managed with antidepressants,
growth factors (i.e. epoetin, granulocyte colony-stimulating factor),
and analgesics.10
Treatment Failure
Individuals who fail to achieve a SVR after initial treatment may be
able to achieve a SVR with a re-treatment regimen of PEG IFN plus
RBV.  A SVR is typically achieved in 25%-40% and 10% of patients
who failed to respond to interferon alfa monotherapy and interferon
alfa plus RBV, respectively.19 AASLD guidelines state that "retreat-
ment with PEG IFN plus RBV should be considered for non-respon-
ders or relapsers who have significant fibrosis or cirrhosis and who
have undergone previous regimens of treatment using non-pegylated
IFN.  Retreatment with PEG IFN plus RBV with the aim of eradicating
HCV is not indicated in patients who have failed to respond to a prior
course of PEG IFN plus RBV, even if a different type of PEG IFN is
administered."11
Normal ALT Levels
The Federal Bureau of Prisons (FBOP) protocol currently states that
the management of HCV-infected inmates should be restricted to
those inmates with an ALT level greater than or equal to two times the
upper limit of normal.20 However, in a given patient, ALT levels may
fluctuate.  Additionally, when other laboratory abnormalities exist (i.e.
low platelet count) further evaluation and/or treatment are indicated.
Current controversy exists regarding whether patients, in whom all
biochemical markers of liver injury are normal and in whom ALT lev-
els are normal on multiple occasions, should be treated.
The 2002 National Institutes of Health (NIH) consensus conference
statement on management of HCV-infected patients with persistently
normal ALT levels stated, "Approximately 30% of patients with chron-
ic HCV infection have normal ALT levels…Although most of these
patients have mild disease, histologically, some may progress to
advanced fibrosis and cirrhosis."21
A recent study evaluated the efficacy and safety of antiviral therapy
for chronic HCV-infected patients with persistently normal ALT levels.
Patients with at least three normal ALT values over an 18 month peri-
od were randomized to receive one of the following: PEG IFN alfa-2a
180 mg/wk plus RBV 800mg/day for 24 weeks, the same combination
for 48 weeks, or no treatment. All patients were monitored for 72
weeks.  An SVR was achieved by 30% and 52% of the patients treat-
ed for 24 and 48 weeks, respectively.  No patient achieved a SVR in
the untreated group.  HCV genotype 1-infected patients achieved
SVR rates of 13% and 40% with 24 and 48 weeks of treatment,
respectively.  HCV genotype 2- or 3-infected patients achieved SVR
rates of 72% and 78% with 24 and 48 weeks of treatment, respec-
tively. While there are no current recommendations regarding whether
to treat patients with normal ALT levels, study authors concluded that
the efficacy and safety of PEG IFN alfa-2a plus RBV for chronic HCV-
infected patients with normal ALT levels is similar to that in patients
with elevated ALT levels.22
HIV/HCV Co-Infection
Among HIV-infected individuals living in the US, nearly 30% are co-
infected with HCV.vi HCV is common in HIV-infected individuals
because of the shared routes of transmission of the two diseases.
While HCV infection often takes 20 to 30 years to progress to cirrho-
sis, the course of HCV is accelerated in the presence of HIV.vi
Aggressive treatment of HIV/HCV co-infected individuals is warrant-
ed, given the potential for increased immunosuppression and
decreased response to antiretroviral therapy (ART.) 
In the AIDS Pegasys Ribavirin Co-Infection Trial (APRICOT) involving
HIV/HCV co-infected patients, 40% and 62% of HCV genotype 1- and
HCV genotype 2- or 3-infected patients, respectively, achieved a
SVR.  These are the highest SVR rates among co-infected patients in
any reported study thus far.23 It should be noted that all participants in
this study had well controlled HIV; viral load averaged 50 µg/ml and
CD4 count averaged 500 cells/ml. In co-infected patients, the duration
of HCV therapy is increased from 24 to 48 weeks for genotype 2- and
3-infected patients. Because of a high relapse rate for genotype 1-
infected patients, extending HCV therapy from 48 to 72 weeks may
improve therapy outcomes. For more information on co-infection,
please refer to the case study in this month's issue.
Why Treat?
Treatment of chronic HCV infection has been shown to be cost-effec-
tive.  In a recent study, a Markov model of disease progression was
constructed to determine if the gain in SVR achieved with PEG IFN
alfa-2a plus RBV would be worth the incremental cost.  In the model,
cohorts of patients received PEG IFN alfa-2a plus RBV for 48 weeks
(genotype 1, genotype non-1 with fibrosis) or 24 weeks (genotype
non-1 without fibrosis.) The model predicted that in HCV genotype 1-
infected patients, PEG IFN alfa-2a plus RBV would increase life-years
(LY) by .78 years and quality adjusted life years by (QALY)i by .67
years, compared with interferon alfa-2b plus RBV.  The associated
cost per LY and QALY gained would be $11,952 and $13,804, respec-
tively.  In HCV genotype non-1-infected patients, PEG IFN alfa-2a
plus RBV would increase LY and QALY by 1.17 and 1.01 years,
respectively, compared with interferon alfa-2b plus RBV; the associ-
ated cost per LY and QALY gained would be $4,132 and $4,772,
respectively.  The study authors concluded that PEG IFN alfa-2a plus
RBV for the treatment of naïve adults with chronic HCV infection,
regardless of HCV genotype, is cost-effective; halting the progression
of disease and avoiding costly future morbidities largely offset costs
associated with treatment.24 Other studies have arrived at similar con-
clusions.25
The correctional environment, with its high HCV prevalence rates
among inmates, provides an opportunity to diagnose and treat popu-
lations at the highest risk of HCV infection.  Because no formal nation-
al guidelines for the treatment of HCV within corrections exist, most
guidelines are system-specific. Research on the implementation of
cost-effective HCV screening, testing, and treatment among the incar-
cerated population is essential.
iEditor's Note:QALY: A year of life adjusted for its quality or its value.
A year in perfect health is considered equal to 1.0 QALY.  The value
of a year in ill health would be discounted.
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Treatment is not recommended for the following:
w Major, uncontrolled depression (interferons 
exacerbate depressive symptoms)
w Renal, heart, lung transplant recipient
w Any condition known to be exacerbated by 
interferon and RBV
w Pregnant women/women who are unable to 
comply with adequate contraception
w Severe concurrent disease (ie - severe 
hypertension)
w Known hypersensitivity to drugs used in 
HCV treatment
Table 3: Treatment Recommendations 
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Dear Colleagues, 
While providing medical care to increasing numbers of inmates, many of us often lose sight
of the dramatic increase in incarceration that has occurred in the United States over the past
two decades.  This steady increase in the numbers of incarcerated individuals has give  the
United States the dubious distinction of being the world's lead incarcerator; we have a greater
proportion of our population behind bars than any other country.  Most of this increase in
incarceration is related to the "war on drugs", which might be more aptly named the "war on
drug users", as that is the population being locked up. As a consequence, there is an
increased prevalence of many diseases associated with addiction in incarcerated popula-
tions. Chief among these is HCV infection.  HCV is most efficiently and most commonly trans-
mitted through shared injection equipment among injection drug users.  With more than one
out of every five inmates infected with HCV, this is clearly a critical problem to address.  
This month, Cassidy, Guidry and Colton tackle the issue of routine screening for HCV.  If peo-
ple become aware of their diagnosis of HCV, they can, at a minimum, learn to avoid alcohol,
the most preventable risk factor for progression to cirrhosis, be vaccinated against Hepatitis
A and B and educated about how to prevent transmission to others. They can also be pre-
pared for clinical evaluation and treatment. Current therapeutic options, although effective,
are associated with predictable toxicities, are expensive, prolonged, and often fail to cure
patients.  Hopefully, in the not too distant future, more effective, less toxic and less expensive
therapies will become available. If more people are aware of their infection, more people will
be prepared to benefit from newer treatments.  Identifying a significant number of the approx-
imately four million individuals in the U.S. infected with HCV could also lead to an increased
demand for resources to be devoted towards developing and implementing better therapies.
Taylor and Mileno present a case highlighting the independent issues in HIV/HCV co-infec-
tion, which is critically important given the accelerated course of HCV disease in people dual-
ly infected with HIV and our IDCR-o-gram describes HCV management and vaccination
schedules.  
More people with chronic HCV pass through correctional systems each year than any other
single institution.  HCV, more than any other disease, underscores the need to view the pro-
vision of public health and health care as a primary mission of correctional facilities. 
Respectfully,  
Jody Rich*, MD, IDCR Editorial Board
Disclosures: *Major Stockhlder: Repligen, Alkermes, Isis
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5Anti-HCV (2nd OR 3rd generation EIA)
Qualitative HCV RNANEGATIVE
IDCR-O-GRAM: Hepatitis C Management Algorithm
Repeat Qualitative
HCV RNA in 6
months to confirm
July 2005     Vol. 8, Issues 7 visit IDCR online at www.IDCRonline.org
Negative or >2 log decrease in
HCV RNA from baseline
<2 log decrease in HCV RNA
from baseline
PositiveNegative
POSITIVE
Obtain HCV genotype, CBC, hepatic function panel, basic metabolic panel, PT, PTT, ferritin, iron, trans-
ferrin saturation, TSH, pregnancy test, HAV Ab total (lgG and lgM), HBsAb lgG and HBsAg, consider
abdominal imaging. Consider liver biopsy.
Genotype 2 or 3*
Continue for an additional 12 weeks
(Total treatment of 24 weeks)
If patient has advanced hepatic fibrosis
consider 48 weeks of therapy
Treatment Week 24
Qualitative HCV RNA
Additional 24 weeks of therapy (total treatment of 48 weeks)
If week 12 HCV RNA positive consider longer duration of therapy
Viral response unlikely (<1%)
Consider D/C or long-term 
PEG-IFN in patients 
with significant fibrosis
During Treatment:CBC at week 2, then CBC, hepatic function panel and basic metabolic panel each month. 
TSH and HCV RNA every three months as clinically indicated.
pegylated interferon alfa-2b
1.5 ug/kg SC once/week
Plus
ribavirin 800mg PO daily
(For genotype 1 consider 
weight-based ribavirin dose)
pegylated interferon alfa-2a
180 ug SC once/week
Plus
ribavirin 1.0-1.2g PO daily for 
genotype 1and 4
ribavirin 800mg PO daily for 
genotype 2 and 3
OR
Refer to package
inserts for dose.
Vaccinate for hepatitis A and/or 
hepatitis B as needed. See chart below.
Stop therapy
Treatment Week 12
Quantitative HCV RNA
Adult Hepatitis Vaccination Schedules
**Editor’s Note: In corrections, dosing schedules may be reduced to 0, 1, 4 months. CDC.  MMWR.  2004; 53(3):681-3.
Hepatitis B Doses and Schedules.  http://digestive.niddk.nih.gov/ddiseases/pubs/vaccinationshepab/#B-doses  Last accessed 11 July 2005.
Adapted from Hepatitis Resource Network, www.h-r-n.org
Editors' Note:*Among HCV genotype 2- or 3-infected patients in whom HCV RNA is undetectable after four weeks of therapy, 12 weeks of treatment is
as effective as 24 weeks.  Mangia, et al.  NEJM.  2005; 352:2609-17.
Type
Hepatitis A
Hepatitis A
Hepatitis B
Hepatitis B
Hepatitis A/B
combination
Vaccine
Havirx
Vaqta
Engerix-B
Recombivax HB (R)
Twinrix (R)
Age
19+
19+
20+
20+
18+
Dose
1440 EI.U
50u
20ug
10ug
720 EI.U Havrix
/20ug Energix-B
# Dose
2
2
3
3
3
Schedule**(months)
0, 6-12
0, 6-12
0, 1, 6
0, 1, 6
0, 1, 6
6ASK THE EXPERT: An HIV/HCV co-infected ex-inmate in need of anti-HCV treatment
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CASE: A HIV/HCV co-infected 49 year-old male presented to a dedicated HIV/HCV co-infection clinic for evaluation of the extent of liver dis-
ease and need for anti-HCV treatment. His CD4 count was 365 cells/mm3, CD4 percentage 28.1% and HIV-1 viral load 195 copies/ml.
Antiretroviral medications included efavirenz 600mg at bedtime, lamivudine 150mg twice daily and stavudine 40mg twice daily. The patient had
been diagnosed with HIV and HCV six years prior while in federal prison and began antiretroviral therapy at that time.  He reported a 20-year
history of injection drug use involving heroin and cocaine along with alcohol abuse.  He denied any drug or alcohol use in the prior seven years
and was active in Narcotic's Anonymous (NA). He had been treated with fluoxetine 10 years earlier when he became depressed following the
death of his partner.  He had suffered multiple stab wounds to the chest 20 years earlier. He was a veteran of the Vietnam War. He was work-
ing full time. He had presented twice before during the prior two years for evaluation for anti-HCV treatment but had declined pharmacotherapy
due to concerns about relapse of addiction and depression. He had recently attended a group education session on the natural history of HCV
in HIV-seropositive persons and the benefits and potential risks of therapy.
On physical exam, vital signs were within normal limits and the patient's affect was bright. There was no icterus, hepatomegaly, splenomegaly,
abdominal mass, shifting dullness, lower extremity edema, jaundice or palmar erythema. There were no spider angiomas. The remainder of the
physical exam was unremarkable. ALT and AST were elevated at 124 IU/mL and 82 IU/mL, respectively.  HCV genotype was 3a. HCV RNA was
396,000 IU/mL. Laboratory tests including BUN, creatinine, electrolytes, CBC with differential, albumin, alkaline phosphatase, total bilirubin, pro-
thrombin time, iron studies, TSH and urinalysis were within normal limits.  
With a genotype of 3a, estimated duration of infection of 27 years (based on first year of injection drug use), elevated ALT, low HCV viral load,
well-controlled HIV and no contraindications to anti-HCV pharmacotherapy, he was strongly encouraged to commence anti-HCV treatment with
the goal of achieving a sustained virologic response (SVR). Given his reluctance, a liver biopsy was performed to determine the extent of fibro-
sis in the hopes of motivating him to be treated. When the biopsy demonstrated  stage 3 of 4 fibrosis (by Batts-Ludwig criteria), he agreed to
undergo anti-HCV treatment.
Q: How should HIV/HCV co-infected patients be treated for HCV? 
Results from trials of pegylated interferon (PEG IFN) plus ribavirin
(RBV) in co-infected patients demonstrate that this regimen is effective
and relatively well-tolerated in HIV-infected individuals.1-3 Although
SVR rates are lower than in HIV/HCV co-infected patients as com-
pared to HCV mono-infected patients, eradication of HCV is achieved
at significantly higher rates with the combination PEG IFN/RBV than
with standard interferon plus RBV or PEG IFN alone. The only FDA-
approved drugs for treatment of HCV in HIV/HCV co-infected patients
are PEG IFN alfa-2a (Pegasys®, Hoffmann-La Roche) plus RBV
(Copegus®, Hoffmann-La Roche), both of which were approved in
February 2005.  
Several sets of evidence-based anti-HCV treatment guidelines have
been developed for co-infected patients.5-9 These guidelines indicate
that all HIV-infected persons should be screened for HCV. HCV RNA
testing should be performed to confirm chronic infection in all persons
with positive HCV serology and in those with negative antibody tests
and unexplained liver disease. All co-infected persons should be con-
sidered for antiviral treatment. This should consist of combination PEG
IFN alpha plus RBV for 48 weeks, irrespective of genotype. The pri-
mary goal of therapy is to eradicate HCV by achieving a SVR.  A sec-
ondary goal is to delay histologic and clinical disease progression.
These goals are consistent with goals for HCV-mono-infected popula-
tions.  A further goal specific to HIV-infected populations is to suppress
HCV disease activity to prevent antiretroviral-related hepatotoxicity.
Co-infected individuals undergoing HCV treatment should be closely
monitored due to the potential for adverse events.
The patient initiated HCV treatment with 180mcg/mL PEG IFN alfa-2a
sq weekly and RBV 400mg orally twice daily. He agreed to weekly clin-
ic visits for PEG IFN administration to optimize adherence, permit
close monitoring and aggressive management of any side effects that
should arise, and provide him with the best chance of completing a full
course of treatment with the recommended dosing. Baseline laborato-
ry values were as follows: CD4 470 cells/mm3, CD4% 26.1%, HIV plas-
ma viral load (PVL) 248 copies/mL, HGB 15.1 G/dL, HCT 42.9%, ANC
2200 K/uL, ALT 159 IU/mL, AST 99 IU/mL and HCV RNA (quantitative)
311,632 IU/mL. He felt well until week four when he complained of
myalgias. Laboratory values were significant for an ANC of 700 K/uL.
At week five he complained of fatigue. Hemoglobin had declined to
11.6 G/dL.
Q: Are there side effects of anti-HCV treatment specific to co-
infected persons?
Hematologic side effects of anti-HCV treatment including anemia, neu-
tropenia and thrombocytopenia can be more common and severe
among co-infected persons than among HCV-mono-infected persons
receiving PEG IFN plus RBV.5-9 The dose-dependent reversible
hemolytic anemia caused by RBV is compounded by the bone marrow
suppressant effect of PEG IFN. In HIV-infected persons, these pre-
dictable effects may be exacerbated by underlying anemia due to
nutritional deficits, concomitant disease or medications such as
zidovudine (AZT).10 Anemia may be managed with dose reduction of
RBV, which can lower treatment efficacy, or by administration of ery-
thropoietin alfa, which can increase hemoglobin levels and enable
maintenance of higher RBV doses.6,8,10Neutropenia, due to PEG IFN-
induced myelosuppression, typically occurs within the first several
weeks of treatment and resolves with PEG IFN cessation.
N utropenia may be managed by dose reduction of PEG IFN, which
can lower treatment efficacy, or with granulocyte colony stimulating
factor (GCS-F).6,8
Consideration must be given to the potential for drug interactions
between anti-HCV medications and nucleoside reverse transcriptase
inhibitors (NRTIs). AZT, which can be associated with anemia, may
interact synergistically with RBV to worsen anemia during anti-HCV
treatment. Options include avoiding AZT during anti-HCV treatment or
closely monitoring hemoglobin, especially during the first weeks of
therapy.7
Mitochondrial toxicity, including fatal lactic acidosis, pancreatitis and
hepatic steatosis are rare effects that may occur with the concomitant
use of RBV and didanosine (ddI), stavudine (d4T) and other NRTIs.6
The proposed mechanism is the inhibition of DNA polymerase gamma,
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7the enzyme responsible for mitochondrial DNA synthesis. The affinity
to DNA polymerase gamma is greatest for ddI, followed by d4T and
then other NRTIs. This inhibition can result in decreased oxidative
phosphorylation and the accumulation of lactate. RBV, a guanosine
nucleoside analogue, can raise levels of intracellular ddATP, the active
metabolite of ddI, increasing the risk for ddI-related mitochondrial tox-
icity. Consequently, co-administration of RBV and ddI is no longer rec-
ommended.5-9 Additionally, cirrhotic co-infected patients receiving ddI
may be at risk for hepatic decompensation.11
The role of d4T in the development of lactic acidosis is possible, but to
a lesser extent than with ddI. The combination of RBV plus d4T may
cause severe weight loss, mimicking the rapid progression of lipoatro-
phy, possibly due to the potentiation of mitochondrial damage in sub-
cutaneous fat.6 It may be beneficial to switch to an alternate antiretro-
viral agent.6 This potential risk was discussed with the patient and he
was given the choice of continuing d4T or substituting an alternate
NRTI. He elected to continue d4T and did not develop complications
related to this medication with anti-HCV therapy.
The patient's neutropenia and symptomatic anemia were supported
with the use of erythropoietin alfa and GCS-F in an attempt to avoid
dose reduction or treatment termination. He received a total of six ery-
thropoietin alfa doses and eighteen GSC-F doses. He completed his
recommended treatment course with no missed PEG IFN doses and
no dose reductions of either PEG IFN or RBV; adherence to weekly
visits for PEG IFN injections was 100%. He worked full-time through-
out the course of therapy. His HCV RNA was undetectable at week 12
of treatment and remained undetectable through the end of treatment.
At the end of treatment his laboratory values were as follows: CD4 385
cells/mm3, CD4 % 27.5%, HIV PVL  <75 copies/mL, HGB 15.2 G/dL,
HCT  43.2%, ANC 2800 K/uL, ALT 41 IU/ mL, AST 33 IU/mL and HCV
RNA PCR <50 IU/mL. Six months after treatment completion his HCV
RNA PCR remained <50 U/mL, consistent with a SVR. Eighteen
months after treatment, his HCV RNA remains non-detectable and he
is thrilled with his accomplishment.
Q: How can the patient's PVL and CD4 changes be explained?
The patient's HIV RNA became non-detectable during the course of
anti-HCV therapy, while the absolute CD4+ cell count declined by 85
cells/mm3 and the CD4+ percentage increased slightly. These findings
are consistent with those of HCV treatment studies in co-infected
patients; individuals with detectable HIV RNA at baseline receiving
PEG IFN experienced a reduction in HIV RNA, suggesting a positive
impact on HIV replication,3,5 and the interferon-induced reduction in
absolute CD4+ count did not impact stability of the CD4+ percentage
nor lead to development of opportunistic infections.5 HIV PVL and CD4
counts/percentages return to baseline levels within several weeks of
treatment cessation. PEG IFN plus RBV does not appear to have a
negative impact on control of HIV.
Q: How was the patient's history of addiction addressed?
Injection drug use is the greatest risk factor for HIV/HCV co-infection.12
Nevertheless, active or recent drug use are among the main reasons
that co-infected persons are not being treated for HCV, given theoret-
ical concerns about addiction relapse or exacerbation and the poten-
tial for re-infection.18-21Populations with HIV, HCV, and addiction have
increased rates of depression and other psychiatric comorbidities.18-21
Additional concerns thus include whether interferon may induce psy-
chiatric symptoms including depression and/or suicidal tendencies.17
Existing data about HCV treatment for drug-involved persons is
promising.22-25 HCV-mono-infected substance using and non-sub-
stance using patients demonstrate similar HCV treatment out-
comes.22,26 Persons with depression and other psychiatric diagnoses
may be safely and effectively treated with interferon-based therapies
with appropriate supports.22, 27-30
This patient's substance use was remote.  He was active in NA.  He
agreed to engage in multidisciplinary care, which has been recognized
as an effective approach to HCV treatment for this population, to mon-
itor and support his mood and addiction status during treatment.31 A
baseline psychiatric evaluation showed adjustment disorder with
mixed mood, which was considered stable.  The recommendation was
to observe only. The patient agreed to monthly visits with the team
psychiatrist for the duration of therapy, weekly PEG IFN medical visits
and occasional meetings with his case manager. He complained of
mild depression and irritability for four weeks but otherwise his course
was uneventful. It should be noted that NA, while often an adequate
self-help program, is not a comprehensive substance abuse treatment
program. Such programs, when available, are an important compo-
nent of the treatment of HCV, and this is consistent with most anti-HCV
treatment guidelines.
Supervised PEG IFN therapy is a promising intervention, allowing for
close monitoring for complications while facilitating adherence.24
Optimizing adherence may also reduce the impact of demographic
variables on SVR. One study in a correctional facility setting suggests
that SVR rates in African-American persons, which have been lower
than those of Caucasians,32 seem to match those of Caucasians when
adherence is optimized.33 The incarcerated setting is an extreme
example of supervised therapy but has been shown to be a feasible
and opportune setting for HCV pharmacotherapy.26,34
ASK THE EXPERT... (continued from page 6)
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HCV Patients Can Overcome Depression 
Currently, the standard of care treatment of
hepatitis C virus (HCV) infection is combination
pegylated interferon (PEG IFN) plus ribavirin
(RBV). However, this regimen may aggravate
already present depressive and psychiatric
symptoms in patients. Kraus, et al. sought to
determine the efficacy of treatment with selec-
tive serotonin re-uptake inhibitor (SSRI) therapy
during secondary prophylaxis (re-treatment) in
patients with chronic HCV. All study participants
were previously unsuccessfully treated with
interferon (IFN) therapy. Seventeen patients in
two groups (prophylaxis and reference) were
included. During initial IFN therapy (before SSRI
prophylaxis), all eight patients, who were later
assigned to the prophylaxis group during re-
therapy, developed signs of a major depressive
episode, according to DSM-IV criteria.  During
re-therapy, patients in the prophylaxis group
received prophylactic SSRI treatment three
weeks before beginning antiviral therapy;
patients in the reference group received antivi-
ral therapy, but did not receive SSRI therapy.
With concomitant SSRI therapy, seven of eight
patients in the prophylaxis group were able to
complete PEG IFN re-therapy. None of the
patients had to discontinue re-therapy due to
psychiatric side effects. Kraus, et al. concluded
that patients with a history of IFN-induced major
depression may be safely re-treated with PEG
IFN plus RBV with concomitant SSRI
prophylaxis.
Kraus M, et al. Journal of Viral Hepatitis. 2005;
12(1):96-100.
Peginterferon alfa-2a Doesn't Alter
Methadone Pharmacokinetics
Sulkowski, et al conducted a study to quantita-
tively evaluate the effects of peginterferon (PEG
IFN) alfa-2a on the pharmacokinetics of
methadone in patients with chronic HCV who
were receiving a stable methadone mainte-
nance regimen.  The 24 subjects enrolled in the
study continued their ongoing daily methadone
maintenance therapy regimen and received 180
ug PEG IFN alfa-2a sq once weekly for four
weeks. The measured pharmokinetic parame-
ters of methadone were no different after four
weeks of dosing than at baseline, despite that
the four-hour methadone levels were increased
by 10-15%. Sulkowski, et al. conclude that con-
current treatment with methadone is not a con-
traindication to therapy with PEG IFN alfa-2a for
chronic HCV and that dose adjustments are not
required.
Sulkowski M, et al. Clinical Pharmacology &
Therapeutics.  2005; 77(3): 214-24.
Effective Treatment for HCV Non-
Responders Examined
A recent retrospective study examined the safe-
ty and efficacy of re-treating HCV non-respon-
ders.  Fifty patients previously treated with PEG
IFN alfa-2 plus RBV, who did not achieve a >2
log10 decrease in HCV RNA at week 12, were
retreated with 15 ug IFN alfacon-1 SQ daily plus
50 ug IFN gamma-1b SQ three times per week
f r 48 weeks.  Thirty-four percent of patients
achieved a sustained virologic response after
re-treatment. A larger, dose-finding study of this
combination treatment is ongoing.
Leevy V, et al.  Poster S1537.  Digestive
Disease Week.  May 13-19, 2005.  Chicago, Il.
FDA Approves Once Daily Kaletra for
Treatment-Naïve Patients
The U.S. Food and Drug Administration (FDA)
approved the use of Kaletra (lopinavir
[LPV]/ritonavir[RTV]) 800/200mg once-daily
administration for the treatment of HIV infection
in therapy-naïve adult patients. Approval for the
new regimen is based on data from two clinical
trials comparing the safety and efficacy of
LPV/RTV 800/200mg once-daily and LPV/RTV
400/100mg twice daily, for a duration of 48
weeks in antiretroviral-naïve HIV-1 infected
patients. The new dosing is available in both liq-
uid and soft gel capsule formulations. At this
time, once daily Kaletra is not approved for
treatment-experienced patients and is not
approved for children. 
www.natap.org
New HCV Drug Under Development
Idenix Pharmaceuticals, Inc, a biopharmaceuti-
cal company based in Cambridge, MA,
announced on May 31 that it has completed
enrollment of its phase IIb clinical trial of valop-
icitabine (NM283) with more than 170 HCV
genotype 1-infected patients who previously
failed at least three months of PEG IFN plus
RBV therapy.  The efficacy and safety of NM283
plus PEG IFN alfa-2a will be compared to the
current stand of care regimen, PEG IFN alfa-2a
plus RBV.  The drug is being developed for use
in both treatment naïve and treatment-experi-
enced patients.
Idenix Pharmaceuticals, Inc.  Press Release
March 31, 2005.  Available at:
http://ir.idenix.com/phoenix.zhtml?c=131556&p
=irol-newsArticle&ID=715016&highlight=  Last
accessed 7 June 2005.
Clinicians Should Monitor for Nephrotoxicity
in TDF-Treated Patients
Tenofovir disoproxil fumarate (TDF), a nucleo-
ide reverse transcriptase inhibitor (NRTI)
approved for the treatment of HIV disease, may
ause nephrotoxicity in TDF-treated patients
with prolonged use, particularly in patients with
advanced HIV disease, diabetes, or a
decreased renal function at baseline. While TDF
has not been associated with nephrotoxicity in
clinical trials, adefovir dipivoxil, a related NRTI,
has caused proximal renal tubular dysfunction
at a dosage of 60-120 mg/day. Clinicians should
assess renal function prior to initiating TDF ther-
apy and continue to monitor renal function in all
TDF-treated patients.
Gallant J, et al.  Clinical Infectious Diseases.
2005; 40: 1194-98.
NEWS AND REVIEWS
RESOURCES
Hepatitis Resource Network: 
www.h-r-n.org 
www.cdc.gov/hepatitis
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Brown Medical School designates this educational activity for one hour in category one credit toward the AMA Physician’s Recognition
Award. To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
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1. Approximately what percent of inmates are infected with HCV?
a. 10%
b. 35%
c. 75%
d. 90%
2. The following statement regarding pegylated interferon/RBV is
not true:
a. Pegylated interferon + RBV is the current standard of care
b. Pegylated interferon + RBV should be administered to 
all HCV-infected patients
c. Pegylated interferon alfa-2a/RBV was approved in 
December 2002
d. Pegylated interferon is available as alfa-2a, alfa-2b, 
and alfa-2c
e. A and B
f. B and D 
3. It is recommended that inmates be screened for 
HCV infection. True or False?
a. True
b. False
4. Which of the following statements is supported by the 
literature?
a. The course of HCV is accelerated in the presence of 
HIV infection.
b. The course of HIV is accelerated in the presence of 
HCV infection.
c. The course of HCV is slowed in the presence of 
HIV infection.
d. The course of HIV is slowed in the presence of 
HCV infection.
5. The ethnic group that has the highest prevalence rate of HCV
genotype 1 infection is:
a. Caucasians
b. African-Americans
c. Pacific Islanders
d. Hispanic
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